Ocuphire Pharma, Inc.

View Ocuphire’s Recent Positive Phase 2 VEGA-1 Topline Data for Presbyopia

View Press Release

Continue

Restoring Vision and Clarity

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of eye disorders.

See Who We Are

A Clear-sighted Product Pipeline

Nyxol®

Targets: Dim Light or Night Vision Disturbances, Pharmacologically-induced Mydriasis, and Presbyopia

Nyxol® Eye Drops is a once-daily preservative-free eye drop formulation designed to reduce pupil size and improve visual acuity.

View Nyxol

APX3330

Targets: Diabetic Retinopathy and Diabetic Macular Edema

APX3330 is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammatory pathways relevant to retinal and choroidal vascular diseases.

View APX3330

Our Clinical Trials

Ocuphire Pharma plans to initiate two Phase 3 registration trials in the fourth quarter of 2020, and two Phase 2 trials in the first quarter of 2021.

View Clinical Trials

Latest News

Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July

View Release

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

View Release

Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

View Release

Stock Snapshot

View Investor Relations